If they did work in combination with neomorphic IDH targeting therapy but failed to cross the blood brain barrier, then they would at least be considered for the treatment of other neomorphic IDH harboring tumors like myeloid neoplasms and chondrosarcoma. The gene discussed is IDH1; the disease is chondrosarcoma.